Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures, and commercializes medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, entered into a licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index. The expanded deal builds on a previous agreement signed ...